Article
Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR.
Current opinion in molecular therapeutics - 1 Jun 2009
Hegymegi-Barakonyi Bálint, Eros Dániel, Szántai-Kis Csaba, Breza Nóra, Bánhegyi Péter, Szabó Gábor Viktor, Várkondi Edit, Peták István, Orfi László, Kéri György
Abstract excerpt
Abnormally elevated EGFR kinase activity can lead to various pathological states, including proliferative diseases such as cancer. The development of selective protein kinase inhibitors has become an important area of drug discovery for the potential treatment of a variety of solid tumors such as breast, ovarian and colorectal cancers, NSCLC, and carcinoma of the head and neck. There are three small molecule EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.